Measuring neutralizing antibodies against COVID-19 using advanced sensors
High-Throughput, Rapid, and Epitope-Specific Quantification of Neutralizing Antibodies Using Digital Nanoparticle Sensors
This study is working on a new, easy way to measure how well your body can fight off the COVID-19 virus by checking for special antibodies, which could help everyone understand their immunity after getting sick or vaccinated.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arizona State University-Tempe Campus NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project ID | NIH-10611462 on NIH RePORTER |
What this research studies
This research focuses on developing a high-throughput method to quantify neutralizing antibodies (nAbs) specific to the SARS-CoV-2 virus. By utilizing digital nanoparticle sensors, the study aims to provide a rapid and efficient way to assess the immune response to COVID-19, which is crucial for understanding immunity levels after infection or vaccination. The approach seeks to overcome limitations of current antibody tests that do not evaluate the functional capacity of antibodies in blocking the virus. This innovative technique could enable broader access to effective testing without the need for specialized laboratory settings.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been vaccinated against COVID-19 or have recovered from a SARS-CoV-2 infection.
Not a fit: Patients who are currently infected with COVID-19 or have not been vaccinated or previously infected may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for assessing immunity to COVID-19, aiding in vaccine development and public health strategies.
How similar studies have performed: Other research has shown promise in using novel technologies for antibody quantification, suggesting that this approach could be effective.
Where this research is happening
Tempe, United States
- Arizona State University-Tempe Campus — Tempe, United States (Active)
Researchers
- Principal investigator: Wang, Chao — Arizona State University-Tempe Campus
- Study coordinator: Wang, Chao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.